NEW YORK (GenomeWeb) – Guardant Health said today that it is working with Bristol-Myers Squibb to develop the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.
Redwood City, California-based Guardant has struck similar partnerships with AstraZeneca, Merck, Merck KGaA, and Pfizer.